Jump to content

Nelonemdaz

From Wikipedia, the free encyclopedia
Nelonemdaz
Legal status
Legal status
  • Investigational
Identifiers
  • 2-Hydroxy-5-[[2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl]methylamino]benzoic acid
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC15H8F7NO3
Molar mass383.222 g·mol−1
3D model (JSmol)
  • C1=CC(=C(C=C1NCC2=C(C(=C(C(=C2F)F)C(F)(F)F)F)F)C(=O)O)O
  • InChI=1S/C15H8F7NO3/c16-10-7(11(17)13(19)9(12(10)18)15(20,21)22)4-23-5-1-2-8(24)6(3-5)14(25)26/h1-3,23-24H,4H2,(H,25,26)
  • Key:HABROHXUHNHQMY-UHFFFAOYSA-N

Nelonemdaz is an experimental drug that works as a free radical reducer and selective antagonist of the NMDA receptor 2b. It is hypothesized to have neuroprotective effects in people who recently experienced a stroke.[1][2][3][4]

References

[edit]
  1. ^ Xu, Xiumei; Chen, Mingyu; Zhu, Dongya (13 October 2023). "Reperfusion and cytoprotective agents are a mutually beneficial pair in ischaemic stroke therapy: an overview of pathophysiology, pharmacological targets and candidate drugs focusing on excitotoxicity and free radical". Stroke and Vascular Neurology. 9 (4): svn–2023–002671. doi:10.1136/svn-2023-002671. PMC 11420919. PMID 37832977.
  2. ^ Lee, Jin Soo; Lee, Ji Sung; Gwag, Byoung Joo; Choi, Dennis W; An, Chun San; Kang, Hyun Goo; Song, Tae-Jin; Ahn, Seong Hwan; Kim, Chang Hun; Kwon, Sun U (February 2023). "Abstract TP15: Rationale And Ongoing Status In A Phase 3 Trial Of Nelonemdaz, A Novel Neuroprotection Drug, For Patients With Acute Ischemic Stroke And Reperfusion". Stroke. 54 (Suppl_1). doi:10.1161/str.54.suppl_1.TP15. S2CID 256564237.
  3. ^ Lee, Jin Soo; Lee, Ji Sung; Gwag, Byoung Joo; Choi, Dennis W.; An, Chun San; Kang, Hyun Goo; Song, Tae-Jin; Ahn, Seong Hwan; Kim, Chang Hun; Shin, Dong-Ick; Kwon, Sun U. (31 January 2023). "The Rescue on Reperfusion Damage in Cerebral Infarction by Nelonemdaz (RODIN) Trial: Protocol for a Double-Blinded Clinical Trial of Nelonemdaz in Patients with Hyperacute Ischemic Stroke and Endovascular Thrombectomy". Journal of Stroke. 25 (1): 160–168. doi:10.5853/jos.2022.02453. PMC 9911845. PMID 36746385.
  4. ^ Hong, Ji Man; Lee, Jin Soo; Lee, Yeong-Bae; Shin, Dong Hoon; Shin, Dong-Ick; Hwang, Yang-Ha; Ahn, Seong Hwan; Kim, Jae Guk; Sohn, Sung-Il; Kwon, Sun U.; Lee, Ji Sung; Gwag, Byoung Joo; Chamorro, Ángel; Choi, Dennis W.; Chammorro, Ángel; Kim, Eung Yeop; Choi, Jin Wook; Yeo, Min-Ju; Kwak, Jaehyuk; Lee, Sung Eun; Hong, Jeong-Ho; Lee, Sangkil; Lee, Yoon-Joo; Lee, Min-Joo (November 2022). "Nelonemdaz for Patients With Acute Ischemic Stroke Undergoing Endovascular Reperfusion Therapy: A Randomized Phase II Trial". Stroke. 53 (11): 3250–3259. doi:10.1161/STROKEAHA.122.039649. PMC 9586831. PMID 36065810.